Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
Zacks.com on MSN11h
Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...
Palantir has burned bears and humbled Wall Street analysts who felt the stock was too rich at half the current price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback